Solutions
- Research Type
  - ETF Data & AnalyticsThe data and analytics you need to navigate the ETF universe.
  - ETF & Mutual Fund ResearchA forward focused, holistic approach to fund insights.
  - Forensic Accounting ResearchUnderstand implications of public company financial reporting.
  - Fundamental Equity ResearchGain a comprehensive view of global themes, industries, and companies.
  - Public Policy & Legal ResearchIdentify opportunity and risk driven by public policy and the courts.
  - Technical ResearchGiving you confidence to navigate any market cycle.
Who We Serve
- Client Type
  - Wealth ManagementFull-service Broker-Dealers, Online Broker-Dealers, Wealth Management Firms, Private Banks, RIAs
  - Institutional InvestorsHedge Funds, Asset Managers, Pension Funds, Sovereign Wealth Funds, Private Equity, Family Offices
  - Financial AdvisorsFinancial Advisors, Relationship Managers, Wealth Managers
  - Individual InvestorsSelf-directed individual investors
Insights
About
- About CFRA
Login

Solutions
- Research Type
  - ETF Data & AnalyticsThe data and analytics you need to navigate the ETF universe.
  - ETF & Mutual Fund ResearchA forward focused, holistic approach to fund insights.
  - Forensic Accounting ResearchUnderstand implications of public company financial reporting.
  - Fundamental Equity ResearchGain a comprehensive view of global themes, industries, and companies.
  - Public Policy & Legal ResearchIdentify opportunity and risk driven by public policy and the courts.
  - Technical ResearchGiving you confidence to navigate any market cycle.
Who We Serve
- Client Type
  - Wealth ManagementFull-service Broker-Dealers, Online Broker-Dealers, Wealth Management Firms, Private Banks, RIAs
  - Institutional InvestorsHedge Funds, Asset Managers, Pension Funds, Sovereign Wealth Funds, Private Equity, Family Offices
  - Financial AdvisorsFinancial Advisors, Relationship Managers, Wealth Managers
  - Individual InvestorsSelf-directed individual investors
Insights
About
- About CFRA
Login

Fundamental, Research

Johnson & Johnson Q1 Earnings Review and Insights on Key Issues

Sel Hardy, Senior Vice President, Equity Research

16 May 2024

Summary

Johnson & Johnson announced Q1 2024 earnings on April 16, 2024, broadly aligning with expectations. In this video, CFRA Senior Vice President of Equity Research Sel Hardy highlights how the MedTech segment is projected to grow faster than Innovative Medicine and the positive growth for JNJ in the M&A of Shockwave Medical (mid-2024) and Ambryx acquisition (closed in March. She also discusses the negative effects of JNJ pushing stock prices up in the short term and the impact of the Inflation Reduction Act drug pricing negotiation process and talc lawsuits on valuations.

Want to learn more? Watch the analyst video and download the report.

Solutions

Fundamental Equity Research

Gain a comprehensive view of global themes, industries, and companies.

Related Insights

Large U.S. Pharmaceuticals: Is M&A the Remedy for Looming Risks Ahead?

Large U.S. Pharmaceuticals: Is M&A the Remedy for Looming Risks Ahead?

Despite the high interest rate environment during 2023, M&A activity in the health care industry...